Imojev
AXP000207.1 · Vaccine
- Platform
- chimeric yellow fever 17D-Japanese encephalitis virus (ChimeriVax)
- Targets
- JEV prM/E
- Originator
- Acambis (ChimeriVax platform) / Sanofi Pasteur
- Sponsor
- Sanofi Pasteur
Names
| Name | Type | Source |
|---|---|---|
| Imojev | preferred name, brand | curator, curator |
| Imojev MD | brand | curator |
| JE-CV | code | curator |
| ChimeriVax-JE | former code | curator |
Virus
- Role
- Vaccine vector
- Family
- Flaviviridae
- Virus
- yellow fever virus (NCBI Taxonomy 11089)
- Strain
- 17D-204 backbone (JE-CV chimera)
- Replication
- replicating
- Modifications
- prM and E genes of YF 17D-204 replaced by those of Japanese encephalitis virus SA14-14-2
- Transgenes
- JEV prM/E
- Route
- subcutaneous
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| other | TH | 2012 | approved | Imojev | Active immunisation against Japanese encephalitis from 12 months of age | source |
| TGA | AU | 2012 | approved | Imojev | Active immunisation against Japanese encephalitis from 12 months of age | source |
Clinical trials (19)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06680128 | A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults | Completed | Phase 1/2 | 2025-02-24 | 2026-07-31 | 161 | Japanese Encephalitis Virus Disease |
| NCT05568953 | An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity | Unknown | Phase 2 | 2022-09-28 | 2025-10 | 70 | Infectious Disease; Japanese Encephalitis; Viral Infection; Yellow Fever |
| NCT03920111 | Flavivirus Cross-priming Potential of IMOJEV | Completed | 2021-04-16 | 2021-12-23 | 19 | Japanese Encephalitis | |
| NCT02933710 | Postmarketing Surveillance Study for IMOJEV® in Republic of Korea | Completed | 2016-07-21 | 2018-10-18 | 50 | Japanese Encephalitis | |
| NCT02492165 | Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects | Completed | Phase 3 | 2015-06 | 2016-03 | 250 | Japanese Encephalitis |
| NCT02526550 | Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX | Completed | Phase 4 | 2014-06 | 2014-07 | 50 | Encephalitis |
| NCT01981967 | Post-licensure Safety Study of IMOJEV® in Thailand | Completed | Phase 4 | 2013-11 | 2015-04 | 10000 | Japanese Encephalitis |
| NCT01954810 | Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children | Unknown | Phase 4 | 2013-10 | 2013-12 | 88 | Japanese Encephalitis |
| NCT01900444 | Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea | Completed | Phase 3 | 2013-07-11 | 2014-03-11 | 119 | Japanese Encephalitis |
| NCT01396512 | Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers | Completed | Phase 3 | 2011-07 | 2013-03 | 274 | Japanese Encephalitis; Japanese Encephalitis Virus Disease |
| NCT01190228 | Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV | Completed | Phase 3 | 2010-08-25 | 2010-10-29 | 454 | Japanese Encephalitis; Varicella |
| NCT01188343 | Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers | Completed | Phase 3 | 2010-08 | 2012-07 | 542 | Japanese Encephalitis; Measles; Mumps; Rubella |
| NCT01092507 | A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers | Completed | Phase 3 | 2010-03 | 2011-09 | 300 | Encephalitis; Japanese Encephalitis |
| NCT01001988 | Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers | Completed | Phase 3 | 2009-08-07 | 2013-10-16 | 596 | Encephalitis; Japanese Encephalitis |
| NCT00735644 | Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines | Completed | Phase 3 | 2008-08 | 2009-05 | 1200 | Hepatitis A; Japanese Encephalitis |
| NCT00621764 | Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children | Completed | Phase 2 | 2008-03 | 2009-12 | 300 | Hepatitis A; Japanese Encephalitis |
| NCT00441259 | Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age | Completed | Phase 2 | 2007-01 | 2011-02 | 96 | Japanese Encephalitis |
| NCT00314132 | Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. | Completed | Phase 3 | 2005-10 | 2006-11 | 2004 | Encephalitis; Japanese Encephalitis |
| NCT00982137 | Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) | Completed | Phase 2 | 2004-07 | 2005-04 | 108 | Japanese Encephalitis; Yellow Fever |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT02602652 | Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine | Completed | 2013-12 | 2015-07 | 50 | Japanese Encephalitis | name in title: JE-CV |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39794472 | Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. | Nature microbiology | 2025 | cited by trial NCT05568953 |
| PMID 36308439 | Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine. | Journal of travel medicine | 2023 | name in abstract: Imojev |
| PMID 36969244 | An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial. | Frontiers in immunology | 2023 | cited by trial NCT05568953 |
| PMID 32474892 | Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev®) in South Korea, 2015-2019. | Infectious diseases and therapy | 2020 | cited by trial NCT02933710 |
| PMID 29081368 | Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2018 | cited by trial NCT02492165 |
| PMID 29325161 | Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines. | The Journal of infectious diseases | 2018 | cited by trial NCT01190228 |
| PMID 27815383 | Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization. | The Journal of infectious diseases | 2017 | cited by trial NCT00621764 |
| PMID 27846060 | Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children. | The Pediatric infectious disease journal | 2017 | cited by trial NCT02526550 |
| PMID 27903416 | Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. | Vaccine | 2017 | cited by trial NCT01981967 |
| PMID 28030526 | Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization. | The Pediatric infectious disease journal | 2017 | name in abstract: Imojev |
| PMID 27686833 | Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. | Vaccine | 2016 | cited by trial NCT00621764 |
| PMID 24631095 | Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. | Vaccine | 2014 | name in title: JE-CV |
| PMID 24656175 | Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. | BMC infectious diseases | 2014 | cited by trial NCT00735644 |
| PMID 24717964 | Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. | The Pediatric infectious disease journal | 2014 | cited by trial NCT01092507 |
| PMID 25483480 | A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. | Human vaccines & immunotherapeutics | 2014 | cited by trial NCT01396512 |
| PMID 23442823 | Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. | Human vaccines & immunotherapeutics | 2013 | name in title: JE-CV |
| PMID 22777096 | Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. | Human vaccines & immunotherapeutics | 2012 | cited by trial NCT00735644 |
| PMID 20856164 | Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. | The Pediatric infectious disease journal | 2010 | cited by trial NCT00621764 |
| PMID 20864814 | Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. | Human vaccines | 2010 | cited by trial NCT00982137 |
| PMID 20934459 | Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. | Vaccine | 2010 | cited by trial NCT00314132 |
| PMID 14551893 | Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. | The Journal of infectious diseases | 2003 | name in title: ChimeriVax-JE |
| PMID 11803060 | Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. | Vaccine | 2002 | name in abstract: ChimeriVax-JE |
Unconfirmed matches (4)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32522414 | Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country. | Vaccine | 2020 | name in abstract: JE-CV |
| PMID 26535878 | Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea. | The Pediatric infectious disease journal | 2016 | name in abstract: JE-CV |
| PMID 27628323 | Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. | Vaccine | 2016 | name in abstract: JE-CV |
| PMID 21150279 | Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. | Human vaccines | 2010 | name in abstract: JE-CV |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41754514 | mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection. | Viruses | 2026 | name in abstract: Imojev |
| PMID 41755551 | Japanese Encephalitis: Understanding Its Impact, Prevention, and the Role of Vaccination. | Reviews in medical virology | 2026 | name in abstract: Imojev |
| PMID 39836415 | Long-term immunogenicity of a single-dose live recombinant chimeric Japanese encephalitis vaccine in adults. | Journal of travel medicine | 2025 | name in abstract: Imojev |
| PMID 40252364 | Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype. | Vaccine | 2025 | name in abstract: Imojev |
| PMID 40982537 | Antibody responses to Japanese encephalitis virus and dengue virus serotype 2 in children from an orthoflavivirus endemic region after IMOJEV vaccination. | PLoS neglected tropical diseases | 2025 | name in title: Imojev |
| PMID 39353860 | Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children. | Human vaccines & immunotherapeutics | 2024 | name in title: Imojev |
| PMID 40295675 | Characterisation of a Japanese Encephalitis virus genotype 4 isolate from the 2022 Australian outbreak. | Npj viruses | 2024 | name in abstract: Imojev |
| PMID 35254947 | Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia. | Human vaccines & immunotherapeutics | 2022 | name in abstract: Imojev |
| PMID 35415706 | Investigation of immune response induction by Japanese encephalitis live-attenuated and chimeric vaccines in mice. | MedComm | 2022 | name in abstract: ChimeriVax-JE |
| PMID 34834244 | Immunological Analysis of Nodavirus Capsid Displaying the Domain III of Japanese Encephalitis Virus Envelope Protein. | Pharmaceutics | 2021 | name in abstract: Imojev |
| PMID 32265332 | A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. | mBio | 2020 | name in abstract: Imojev |
| PMID 32546414 | Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017-18. | Vaccine | 2020 | name in title: Imojev |
| PMID 30230947 | Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine. | Human vaccines & immunotherapeutics | 2019 | name in abstract: Imojev |
| PMID 26588242 | Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children. | Expert review of vaccines | 2016 | name in title: Imojev |
| PMID 25841620 | Current recommendations for the Japanese encephalitis vaccine. | Journal of the Chinese Medical Association : JCMA | 2015 | name in abstract: Imojev |
| PMID 25134477 | Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine. | Infectious diseases and therapy | 2013 | name in title: ChimeriVax-JE |
| PMID 22775524 | Clinical development of IMOJEV ®--a recombinant Japanese encephalitis chimeric vaccine (JE-CV). | Expert opinion on biological therapy | 2012 | name in title: Imojev |
| PMID 21434803 | New Japanese encephalitis vaccines: alternatives to production in mouse brain. | Expert review of vaccines | 2011 | name in abstract: Imojev |
| PMID 19913267 | Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus. | Virology | 2010 | name in abstract: ChimeriVax-JE |
| PMID 20130134 | An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. | The Journal of general virology | 2010 | name in abstract: ChimeriVax-JE |
| PMID 20218889 | Japanese encephalitis: new options for active immunization. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2010 | name in abstract: ChimeriVax-JE |
| PMID 21105774 | IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine. | Expert review of vaccines | 2010 | name in title: Imojev |
| PMID 21308526 | New vaccines for Japanese encephalitis. | Current infectious disease reports | 2010 | name in abstract: ChimeriVax-JE |
| PMID 19109382 | Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. | Journal of virology | 2009 | name in abstract: ChimeriVax-JE |
| PMID 19768415 | Microneedle-based vaccines. | Current topics in microbiology and immunology | 2009 | name in abstract: ChimeriVax-JE |
| PMID 17303204 | A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. | Virology | 2007 | name in abstract: ChimeriVax-JE |
| PMID 17693000 | Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). | Vaccine | 2007 | name in title: ChimeriVax-JE |
| PMID 17038690 | Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). | The American journal of tropical medicine and hygiene | 2006 | name in title: ChimeriVax-JE |
| PMID 15975826 | Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. | Biologicals : journal of the International Association of Biological Standardization | 2005 | name in abstract: ChimeriVax-JE |
| PMID 16273137 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2005 | name in abstract: ChimeriVax-JE |
| PMID 17012854 | Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. | Human vaccines | 2005 | name in title: ChimeriVax-JE |
| PMID 15176941 | A chimeric live attenuated vaccine against Japanese encephalitis. | Expert review of vaccines | 2004 | name in abstract: ChimeriVax-JE |
| PMID 15315852 | Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. | Vaccine | 2004 | name in title: ChimeriVax-JE |
| PMID 12949633 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2003 | name in abstract: ChimeriVax-JE |
| PMID 14508887 | ChimeriVax-JE. Acambis. | Current opinion in investigational drugs (London, England : 2000) | 2003 | name in title: ChimeriVax-JE |
| PMID 11799188 | Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. | Journal of virology | 2002 | name in abstract: ChimeriVax-JE |
| PMID 12082985 | Japanese encephalitis vaccines: current vaccines and future prospects. | Current topics in microbiology and immunology | 2002 | name in abstract: ChimeriVax-JE |
| PMID 11134306 | Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). | Journal of virology | 2001 | name in title: ChimeriVax-JE |
| PMID 10644345 | Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. | Journal of virology | 2000 | name in abstract: ChimeriVax-JE |
| PMID 11220763 | Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. | The American journal of tropical medicine and hygiene | 2000 | name in title: ChimeriVax-JE |
| PMID 10217584 | Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. | Vaccine | 1999 | name in abstract: ChimeriVax-JE |
| PMID 10329547 | Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. | Virology | 1999 | name in title: ChimeriVax-JE |
Unconfirmed matches (5)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42363922 | Japanese Encephalitis Vaccine Preferences and Uptake in Western Travelers and Locals: Strategies to Enhance Vaccine Uptake. | Value in health regional issues | 2026 | name in abstract: JE-CV |
| PMID 42728503 | Immunogenicity of a Vero cell-adapted Japanese encephalitis attenuated virus strain SA14-14-2 VC6. | Archives of virology | 2026 | name in abstract: JE-CV |
| PMID 37782654 | Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010-2022. | PLoS neglected tropical diseases | 2023 | name in abstract: JE-CV |
| PMID 33974924 | Feasibility of chitosan-based nanoparticles approach for intranasal immunisation of live attenuated Japanese encephalitis vaccine. | International journal of biological macromolecules | 2021 | name in abstract: JE-CV |
| PMID 22342547 | Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. | Vaccine | 2012 | name in abstract: JE-CV |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| U01AI070350 | Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis | UNIVERSAL STABILIZATION TECHNOLOGIES | BRONSHTEIN, VICTOR | 2006–2008 | name in abstract: ChimeriVax-JE |
Notes
Live chimeric virus: yellow fever 17D-204 backbone with the prM and E genes of JEV SA14-14-2. Same 'carries something foreign' reasoning as CYD-TDV. Single subcutaneous dose from 12 months of age. WHO-prequalified 2014-09-18 with the Thai FDA as national regulatory authority of record. Exact national approval dates were not found on an agency page; the Thai and Australian rows are dated 2012 from the launch press releases that state marketing authorisation had been granted.
How to cite
Imojev (AXP000207.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000207.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.